Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Cue Biopharma, Inc. (CUE)

Pharmaceutical Preparations

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

40 GUEST STREET
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/02/2018

Market Cap

32,634,790

Shares Outstanding

45,120,000

Weighted SO

45,123,281

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

COYA --.--%

LTRN --.--%

FENC --.--%

ELYM --.--%

ANIX --.--%

INMB --.--%

INAB --.--%

PYPD --.--%

XFOR --.--%

Beta

1.9540

Last Div

0.0000

Range

0.583-3.249

Chg

0.0770

Avg Vol

452598

Mkt Cap

32634790

Exch

NASDAQ

Country

US

Phone

617 949 2680

DCF Diff

4.2337

DCF

-2.0537

Div Yield

0.0000

P/S

3.9338

EV Multiple

-0.3150

P/FV

1.5569

Div Yield %

0.0000

P/E

-0.7169

PEG

-0.0288

Payout

0.0000

Current Ratio

2.0597

Quick Ratio

2.0597

Cash Ratio

1.8245

DSO

81.2627

DIO

0.0000

Op Cycle

81.2627

DPO

416.5031

CCC

-335.2404

Gross Margin

0.5874

Op Margin

-5.8034

Pretax Margin

-5.6602

Net Margin

-5.6602

Eff Tax Rate

-0.0493

ROA

-1.1093

ROE

-1.4293

ROCE

-1.8610

NI/EBT

1.0000

EBT/EBIT

0.9753

EBIT/Rev

-5.8034

Debt Ratio

0.2197

D/E

0.4302

LT Debt/Cap

0.0956

Total Debt/Cap

0.3008

Int Coverage

-58.7851

CF/Debt

-4.1427

Equity Multi

1.9577

Rec Turnover

4.4916

Pay Turnover

0.8763

Inv Turnover

0.0000

FA Turnover

1.5147

Asset Turnover

0.1960

OCF/Share

-0.7679

FCF/Share

-0.7692

Cash/Share

0.5985

OCF/Sales

-4.6445

FCF/OCF

1.0017

CF Coverage

-4.1427

ST Coverage

-5.4927

CapEx Coverage

-592.7846

Div&CapEx Cov

-592.7846

P/BV

1.5569

P/B

1.5569

P/S

3.9338

P/E

-0.7169

P/FCF

-0.8455

P/OCF

-0.8736

P/CF

-0.8736

PEG

-0.0288

P/S

3.9338

EV Multiple

-0.3150

P/FV

1.5569

DPS

0.0000

Latest Headlines (EST)

Benzinga Apr 15, 02:23 Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering GlobeNewswire Inc. Apr 15, 02:23 Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering GlobeNewswire Inc. Nov 29, 21:30 Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Sep 27, 03:26 Cue Biopharma Announces Pricing of $12.0 Million Public Offering GlobeNewswire Inc. Dec 20, 09:33 CUEN – Cuentas, Inc. Envisions Double Digit Growth in the Vibrant South Florida Real Estate Market, Anticipating Lower Interest Rates, and Strategically Leveraging Its 10-Year Supply Agreement of Pioneering Composite Building Technology. GlobeNewswire Inc. Dec 11, 10:16 CUEN – Unleashes the Power of Shareholder Influence – Unveils Proxy Vote Link and Ignites a Call to Action GlobeNewswire Inc. Nov 30, 08:30 CUEN – CEO Unveils Shareholder Letter Highlighting Advances in Acquisitions, Real Estate, and Cutting-Edge Construction Technology, Alongside an Anticipated Shareholder Meeting GlobeNewswire Inc. Nov 21, 08:30 CUEN – Cuentas Unveils State-of-the-Art Disaster-Resilient Buildings in Florida, tapping into a $2.1 Trillion Market to Reshape Real Estate's Future GlobeNewswire Inc. Nov 20, 08:30 CUEN - Cuentas Achieves Remarkable Third Quarter Results, Showcasing an Astounding 861% Revenue Surge Compared to the Previous Quarter in 2023, Alongside a Noteworthy 200% Year-over-Year Growth in Cash Position.

Revenue Product Segmentation